Critical pathomechanisms of NSAID-exacerbated respiratory disease (N-ERD) clarified by treatment with omalizumab, an anti-IgE antibody
Allergology International · 2025-01 · 74 (1) · 51-65
DOI: 10.1016/j.alit.2024.08.008 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Allergology International, 2025-01. Verfasst von Hiroaki Hayashi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, Japan; Department of …. Hauptthemen laut MEDLINE: Omalizumab, Anti-Inflammatory Agents, Non-Steroidal. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 253 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japanese Society of Allergology, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Characteristic symptoms of NSAID-exacerbated respiratory disease (N-ERD) include asthma, chronic eosinophilic rhinosinusitis with nasal polyposis, cysteinyl LT (CysLT) overproduction and NSAIDs hypersensitivity. Some N-ERD patients present with episodic treatment-resistant extra-respiratory symptoms (CysLT-associated coronary artery vasospasm, gastroenteritis, or skin rash). Even when using standard treatments for respiratory and extra-respiratory symptoms, including systemic corticosteroids and aspirin desensitization, it is difficult to control the clinical symptoms and severe type 2 inflammation involved with mast cells, eosinophils, ILC2s, and platelet activation. Few treatment options are applicable in a clinical setting. Therefore, identifying effective treatments is essential for managing N-ERD patients who suffer from these conditions. Our previous observational study demonstrated 12-month omalizumab treatment of N-ERD was clinically effective against respiratory symptoms. Despite the remaining eosinophilia, omalizumab significantly reduced urinary LTE4 and PGD2 metabolites to near normal levels at steady state. Based on the preliminary study, we demonstrated that omalizumab induced tolerance to aspirin in N-ERD patients 3 months after therapy initiation and suppressed activation of mast cells during 24 h of initiation in a randomized manner. Moreover, omalizumab had significant efficacy against extra-respiratory symptoms at baseline (lacking aspirin exposure) as well as throughout aspirin challenge. This review addresses the latest discoveries related to N-ERD pathogenesis and the significant effectiveness of omalizumab on N-ERD as a mast cell stabilizer. Our findings regarding omalizumab-associated mast cell inhibitory effects are indirect evidence that mast cell dysregulation and, possibly, IgE are pivotal components of N-ERD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, Japan; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, N…
- Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan; National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
- Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, Japan.
Förderung
- Japanese Society of Allergology
- Japan Agency for Medical Research and Development
Zitieren
APA
Hayashi, H., Ishii, M., Hasegawa, Y., & Taniguchi, M. (2025). Critical pathomechanisms of NSAID-exacerbated respiratory disease (N-ERD) clarified by treatment with omalizumab, an anti-IgE antibody. Allergology International, 74(1), 51-65. https://doi.org/10.1016/j.alit.2024.08.008
Vancouver
Hayashi H, Ishii M, Hasegawa Y, Taniguchi M. Critical pathomechanisms of NSAID-exacerbated respiratory disease (N-ERD) clarified by treatment with omalizumab, an anti-IgE antibody. Allergology International. 2025;74(1):51-65. doi:10.1016/j.alit.2024.08.008
BibTeX
@article{Hayashi2025,
author = {Hayashi, Hiroaki and Ishii, Makoto and Hasegawa, Yoshinori and Taniguchi, Masami},
title = {Critical pathomechanisms of NSAID-exacerbated respiratory disease (N-ERD) clarified by treatment with omalizumab, an anti-IgE antibody},
journal = {Allergology International},
year = {2025},
volume = {74},
number = {1},
pages = {51--65},
doi = {10.1016/j.alit.2024.08.008}
}
EUVIMED